Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 7/20 | 0.76 |
| ▸ | HTR1D | P28221 | 5/20 | 0.76 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | HTR6 | P50406 | 10/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8209125 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6HTR2A | |
| SCHEMBL30053794 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6HTR2A | |
| SCHEMBL29206476 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6HTR2A | |
| SCHEMBL29827365 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6HTR2A | |
| SCHEMBL29206389 | 0.90 | HTR6 (0.69) | HTR1BHTR1DHTR1AHTR6HTR2A | |
| SCHEMBL29206499 | 0.87 | HTR1B (0.60) | HTR1BHTR1DHTR1AHTR6 | |
| SCHEMBL29206495 | 0.87 | HTR1B (0.60) | HTR1BHTR1DHTR1AHTR6 | |
| SCHEMBL30877230 | 0.87 | HTR1B (0.60) | HTR1BHTR1DHTR1AHTR6 | |
| SCHEMBL8208343 | 0.86 | HTR1B (1.00) | HTR1BHTR1DHTR1AHTR6 | |
| SCHEMBL8508432 | 0.86 | HTR1B (1.00) | HTR1BHTR1DHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957211-A | Fluorinated tryptamine compounds, analogs thereof, and methods of use thereof | 圣约瑟夫大学 | 2024-04-30 | — | — | CN | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | disclosed |
| CN-119546591-A | Indoline derivatives as serotonergic agents for the treatment of related disorders | 思维模式制药公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511369-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-02-26 | — | — | EP | disclosed |
| US-20240286998-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | SAINT JOSEPH'S UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | disclosed |
| CN-117957211-A | Fluorinated tryptamine compounds, analogs thereof, and methods of use thereof | 圣约瑟夫大学 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023201423-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023201423-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| CN-102936240-A | Synthetic method of (R)-5-substituted-3-(N-carbobenzoxy pyrrolidine-2-based carbonyl)-1H-benzpyrole | ZHEJIANG ACADEMY MEDICAL SCI | 2013-02-20 | — | — | CN | disclosed |
| US-6100291-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-08-08 | — | — | US | disclosed |
| CN-1039322-C | Indole derivatives | PFIZER (US) | 1998-07-29 | — | — | CN | disclosed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240286998-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | TPH2, TPH1, HNMT | HTR1B 12/4885HTR1D 27/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.